Abstract 323P
Background
Ovarian cancer is a general phrase that may be applied to any malignancy that affects the ovaries and is one of the worst malignancies. Aside from the number of its population, the Asian population also has a very diverse culture and socioeconomic development. Pretreatment peripheral blood cell counts, including lymphocytes, monocytes, and neutrophils, are major prognostic indicators in various cancers. This study aimed to evaluate the role of NLR, PLR, and LMR as prognostic biomarkers in ovarian cancer among the Asian population in a meta-analysis design.
Methods
This study assessed the association between NLR, PLR, and LMR and ovarian cancer as prognostic biomarkers based on the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) protocol. The literature research was performed by systematically searching PubMed, ScienceDirect, and Google Scholar using the search terms based on BOOLEAN operators. Revman software ver 5.4.1 was employed for all statistical analyses, and p-values<0.05 were considered statistically significant.
Results
This study included 17 studies conducted in various Asian countries according to inclusion and exclusion criteria. Significant results were found in both univariate and multivariate analysis for NLR, PLR, and LMR to overall survival [(Univariate) NLR: HR 2.04; 95% CI 1.61 – 2.58; p<0.001, PLR: HR 2.04; 95% CI 1.26 – 3.30; p<0.001, LMR: HR 0.53; 95% CI 0.40 – 0.72; p<0.001. (Multivariate) NLR: HR 1.65; 95% CI 1.22 – 2.22; p<0.001, PLR: HR 2.12; 95% CI 1.70 – 2.66; p<0.001, LMR: HR 0.54; 95% CI 0.37 – 0.80; p=0.002]. Significant results were also found in both univariate and multivariate analysis for NLR and PLR to disease-free survival [(Univariate) NLR: HR 2.19; 95% CI 1.36 – 3.54; p<0.001, PLR: HR 1.95; 95% CI 1.31 – 2.91; p<0.001. (Multivariate) NLR: HR 1.37; 95% CI 1.21 – 1.56; p<0.001, PLR: HR 1.78; 95% CI 1.45 – 2.17; p<0.001.
Conclusions
NLR, PLR, and LMR can be considered as prognostic biomarkers in ovarian cancer. Further studies are needed to re-evaluate these findings in the Asian population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
I.G.P. Supadmanaba.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
497P - Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial
Presenter: Ying Jin
Session: Poster Display
Resources:
Abstract
498P - Frailty-adjusted life expectancy and survival in older lung cancer patients: A large-scale electronic health-record based study
Presenter: Thao Tu
Session: Poster Display
Resources:
Abstract
499P - Long-term survival and treatment (tx) patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC): Japanese cohort of a global real-world (rw) observational study
Presenter: Daichi Fujimoto
Session: Poster Display
Resources:
Abstract
500P - The effectiveness and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer: Real-world, multicenter, observational study (NEJ056)
Presenter: Hidehito Horinouchi
Session: Poster Display
Resources:
Abstract
501P - One-year survival outcomes of unresectable stage III non-small cell lung cancer patients who underwent PD-1 inhibitor plus chemo as induction therapy
Presenter: Xin Wang
Session: Poster Display
Resources:
Abstract
502P - Impact of sarcopenia on the outcome of patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
Presenter: Kentaro Tamura
Session: Poster Display
Resources:
Abstract
503P - Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with locally advanced NSCLC
Presenter: TSUYOSHI HIRATA
Session: Poster Display
Resources:
Abstract
504P - Real-world outcomes with induction systemic therapy for stage III in eligible for upfront local therapy: Pre vs post immunotherapy era in a tertiary referral centre
Presenter: Praveen Kumar Marimuthu
Session: Poster Display
Resources:
Abstract
505P - Neoadjuvant PD-1 inhibitor (tislelizumab) plus platinum–etoposide in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Junjie Hu
Session: Poster Display
Resources:
Abstract
506P - Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: Implications for thoracic radiotherapy
Presenter: Byoung Hyuck Kim
Session: Poster Display
Resources:
Abstract